AEterna Zentaris (AEterna Zentaris) Additional Paid-In Capital : $90.71 Mil(As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Additional Paid-In Capital?

AEterna Zentaris's quarterly additional paid-in capital increased from Jun. 2023 ($90.65 Mil) to Sep. 2023 ($90.68 Mil) and increased from Sep. 2023 ($90.68 Mil) to Dec. 2023 ($90.71 Mil).

AEterna Zentaris's annual additional paid-in capital increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($90.33 Mil) and increased from Dec. 2022 ($90.33 Mil) to Dec. 2023 ($90.71 Mil).

AEterna Zentaris Additional Paid-In Capital Historical Data

The historical data trend for AEterna Zentaris's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Additional Paid-In Capital Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

90.33

90.71

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															90.33	-	90.65	90.68	90.71

AEterna Zentaris Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

AEterna Zentaris Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.